New CPT codes approved for bivalent COVID-19 vaccines for young children

The American Medical Association (AMA) released four new Current Procedural Terminology (CPT^®) codes for bivalent COVID-19 vaccines for young children. After receiving FDA authorization, CPT codes 91316, 91317, 0164A, and 0173A became effective on December 8.

The descriptors for the new codes are as follows:

• Moderna bivalent—6 months through 5 years
  
  • 91316: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use
  • 0164A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster dose
• Pfizer-BioNTech bivalent—6 months through 4 years
  
  • 91317: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
  • 0173A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose

Further information on codes 91316 and 0164A can be found in the AMA’s CPT® Assistant Special Edition: November Update. The December issue details codes 91317 and 0173A.

The AMA offers a resource to help find the appropriate CPT code combination for type and dose of COVID-19 vaccines. Additional information can be found in the COVID-19 Provider Toolkit.

Editor's note: Find more NAHRI resources on COVID-19 vaccines here.